The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.
ENROLLING_BY_INVITATION
Status
Conditions
Interventions
- DRUG: SCFA → Placebo (Sequence SP) and Placebo → SCFA (Sequence PS)
Sponsor
University Hospital, Martin